Gastroesophageal reflux disease is linked with frailty, shorter leukocyte telomeres and higher neurodegenerative disease risk in human cohorts. GLP-1 receptor agonist use is linked with higher reflux risk in people with diabetes and obesity but lower risk after bariatric surgery. A human trial reports less reflux with Nissen sleeve gastrectomy than standard sleeve gastrectomy.
47 findings in 33 papers from 2016 to 2026, 8 of them since July 2026
“clinical GERD incidence 57.9% versus 18.8% (effect size: .23 [.07; .73], P = .01) for the SG and NSG groups, respectively.”
Roux-en-y gastric bypass is linked with lower gastroesophageal reflux disease in humans (revisional surgery after sleeve gastrectomy) (95 vs. 5%, p = 0.02).
“RYGB yielded markedly better GERD resolution (95 vs. 5%, p = 0.02)”
Humansrevisional surgery after sleeve gastrectomy7 yearsn = 105
Statins were not clearly linked with gastroesophageal reflux disease in humans (Genetically proxied through HMGCR-mediated LDL-C reduction) (OR 0.999, 95% CI 0.992–1.006).
“No significant causal association was found between statin use and gastroesophageal reflux disease (OR = 0.999, 95% CI: 0.992-1.006, p = 0.773).”
HumansGenetically proxied through HMGCR-mediated LDL-C reductionn = 462,933
Alcohol was not clearly linked with gastroesophageal reflux disease in humans (Without GERD at baseline) (HR 1.00 (95% CI 0.98–1.03)).
“Each healthy lifestyle, except for moderate alcohol intake (hazard ratios [HR], 1.00; 95% confidence interval [CI]: 0.98-1.03) was associated with a lower risk of GERD.”
HumansWithout GERD at baselineModerate intakeMean follow-up of 12.7 yearsn = 306,543
GLP-1 receptor agonists are associated with gastroesophageal reflux disease in humans (ROR 2.83 (95% CI 2.39 to 3.35) in FAERS; JADER 4.76; Canada Vigilance 2.91).
“significant GERD signals were detected across all databases: FAERS (ROR, 2.83; 95% CI, 2.39 to 3.35; 9,245 vs 139)”
GLP-1 receptor agonists are linked with a higher risk of gastroesophageal reflux disease in humans (patients with diabetes mellitus and obesity, propensity-matched against controls).
“GERD (HR 1.18 [1.14, 1.22])”
Humanspatients with diabetes mellitus and obesity, propensity-matched against controls1 yearn = 164,987
GLP-1 receptor agonists are linked with a lower risk of gastroesophageal reflux disease in humans (postoperative use versus non-use after bariatric surgery) (RR 0.645 (95% CI 0.539-0.773)).
“GERD (RR 0.645; 95% CI: 0.539-0.773; p<0.001)”
Humanspostoperative use versus non-use after bariatric surgeryfive yearsn = 6,571
Gastroesophageal reflux disease is associated with frailty in silico.
“Our research provided strong evidence of genetic correlation between GERD and several age-related phenotypes, especially frailty index (FI) and telomere length (TL)”
Healthy lifestyle is associated with gastroesophageal reflux disease in humans (Without GERD at baseline) (HR 0.63 (95% CI 0.60–0.66), score 5–7 versus less than 2; P for trend <0.001).
“those with 2, 3, 4, and 5-7 of this score showed a significantly lower risk of GERD”
HumansWithout GERD at baselineHealthy lifestyle score 5–7 versus less than 2Mean follow-up of 12.7 yearsn = 306,543
Gastroesophageal reflux disease is associated with bladder cancer in silico (two-sample Mendelian randomization meta-analysis) (OR 1.254, 95% CI 1.047-1.501).
“Suggestive positive associations were also observed for laryngeal cancer (OR = 1.774; 95% CI: 1.091-2.884; P = .021) and bladder cancer (OR = 1.254; 95% CI: 1.047-1.501; P = .014)”
In silicotwo-sample Mendelian randomization meta-analysis
Gastroesophageal reflux disease is associated with laryngeal cancer in silico (two-sample Mendelian randomization meta-analysis) (OR 1.774, 95% CI 1.091-2.884).
“Suggestive positive associations were also observed for laryngeal cancer (OR = 1.774; 95% CI: 1.091-2.884; P = .021) and bladder cancer (OR = 1.254; 95% CI: 1.047-1.501; P = .014)”
In silicotwo-sample Mendelian randomization meta-analysis
Gastroesophageal reflux disease raises the risk of lung cancer in silico (OR 1.190, 95% CI 1.040-1.362).
“In Multivariable Mendelian randomization analyses accounting for body mass index, smoking intensity, and alcohol consumption, the association with lung cancer remained statistically significant (OR = 1.190; 95% CI: 1.040-1.362; P = .012)”
In silicomultivariable Mendelian randomization accounting for body mass index, smoking intensity, and alcohol consumption
Semaglutide is associated with gastroesophageal reflux disease in humans (versus dipeptidyl peptidase-4 inhibitors) (ROR 3.44 to 6.93 across databases).
“Drug-specific analyses revealed the strongest signals for semaglutide across all databases (3.44 to 6.93)”
Nissen sleeve gastrectomy lowers the risk of gastroesophageal reflux disease in humans (versus standard sleeve gastrectomy) (18.8% vs 57.9% (effect size: .23 [.07; .73], P = .01)).
“clinical GERD incidence 57.9% versus 18.8% (effect size: .23 [.07; .73], P = .01) for the SG and NSG groups, respectively.”
Human trialversus standard sleeve gastrectomy5 yearsn = 82
Gastroesophageal reflux disease is linked with frailty and neurodegenerative disease in human cohorts, while shorter leukocyte telomeres are associated with greater reflux risk. GLP-1 receptor agonist associations point both ways: higher risk in people with diabetes and obesity, but lower risk after bariatric surgery. A human trial reports lower reflux risk after Nissen sleeve than standard sleeve gastrectomy.
Summary rewritten as its findings changed.
As it read before
An in silico Mendelian randomization study links gastroesophageal reflux disease to higher lung cancer risk after accounting for body mass index, smoking intensity and alcohol consumption, and to bladder and laryngeal cancers.
Median male-to-female activity-duration ratios were 0.90 for death from any cause, 1.37 for heart and blood vessel disease deaths, and 0.71 for cancer deaths.Median male-to-female activity-duration ratios were 0.90 for death from any cause, 1.37 for heart and blood vessel disease deaths, and 0.71 for cancer deaths.